Cargando…
Systemic Therapy for Invasive Bladder Cancer: The Value Proposition
Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy followed by definitive local treatment should be the treatment of choice for otherwise healthy and robust patients with T2b–T4 invasive bladder cancer.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AlphaMed Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912376/ https://www.ncbi.nlm.nih.gov/pubmed/27125752 http://dx.doi.org/10.1634/theoncologist.2016-0074 |
| Sumario: | Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy followed by definitive local treatment should be the treatment of choice for otherwise healthy and robust patients with T2b–T4 invasive bladder cancer. |
|---|